Haleon’s core business model is grounded in branded consumer health products with a strong emphasis on innovation-led premiumization and geographic diversification that supports growth resilience. Its supply chain productivity initiatives provide a defensible margin advantage and financial flexibil…
Haleon (HLN) H1 2025: Operating Profit Up 9.9% on 3.2% Organic Revenue Growth Despite North America Challenges
Haleon delivered strong organic operating profit growth driven by productivity gains and brand investment, offsetting a subdued North American consumer environment. Momentum in EMEA, Latin America, and Asia-Pacific, led by Oral Health innovation, supports upgraded full-year profit guidance. The company’s disciplined capital allocation and supply chain productivity underpin financial flexibility amid ongoing U.S. market headwinds.
Summary
- Global Growth Resilience: Robust volume and price growth in EMEA, LatAm, and Asia-Pacific offset North American softness.
- Productivity-Driven Margin Expansion: Supply chain simplification and SKU rationalization delivered 160 basis points gross margin improvement.
- Strategic Investment Balance: Increased advertising and R&D spend supports innovation-led premiumization and market penetration.
Business Overview
Haleon is a global consumer health company focused on delivering everyday health products across six major categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company generates revenue primarily through branded product sales distributed worldwide, with key geographic segments in North America, Europe, Middle East, Africa and Latin America (EMEA and LatAm), and Asia-Pacific (APAC).
Performance Analysis
For the six months ended June 30, 2025, Haleon reported a 3.2% organic revenue increase to £5.48 billion, driven by a 2.4% price increase and a 0.8% volume/mix improvement. This growth was largely powered by strong performances in EMEA & LatAm (+5.2%) and APAC (+5.0%), which partially offset a modest 0.4% organic decline in North America amid a weak U.S. consumer and retail environment. Oral Health, a critical growth driver, delivered an impressive 7.6% organic revenue increase, underscoring the impact of innovation-led premiumization and market penetration.
Adjusted operating profit rose 9.9% to £1.24 billion, with margin expansion of 140 basis points to 22.7%. This margin improvement was underpinned by a 160 basis point organic gross profit margin expansion, reflecting the early benefits of the company’s supply chain productivity program focused on SKU rationalization, manufacturing efficiencies, and logistics optimization. Despite increased advertising and promotional (A&P) spend, up 6.8% to 20.8% of sales, and R&D investment up 9.1%, the company maintained strong operating leverage. Free cash flow was robust at £734 million, up £184 million year-over-year excluding one-time divestment proceeds, driven by working capital improvements and lower restructuring costs.
- North America Drag: Organic sales declined 0.4%, reflecting challenging consumer confidence, trade-down to value channels, and inventory destocking by drug retailers.
- EMEA and LatAm Strength: Delivered 5.2% organic revenue growth, supported by volume acceleration and strong Oral Health innovation uptake.
- Asia-Pacific Volume Acceleration: Volume growth improved to 3.9% in Q2, contributing to overall 5.0% organic revenue growth for the segment.
Overall, Haleon’s diversified geographic footprint and category mix provided resilience against U.S. market headwinds, enabling the company to upgrade its full-year guidance to high single-digit organic operating profit growth while maintaining a 3.5% organic revenue growth outlook.
Executive Commentary
"We delivered a good performance across EMEA & LatAm and Asia Pacific, partly offset by a weaker environment in North America. Oral Health grew strongly, driven by new innovations. I am pleased with the significant progress we are already making with our productivity programme to simplify our supply chain and drive gross profit margin. This contributed to our strong organic operating profit growth while investing in A&P and R&D. As a result, we are upgrading our guidance to high-single digit organic operating profit growth for the year."
Brian McNamara, Chief Executive Officer
"The benefit from our supply chain productivity has enabled us to continue to invest in advertising and promotion and research and development, while delivering strong margin expansion. We have improved ROI on our AMP spend by 4% and expect to maintain a similar investment shape in the second half, focusing on growth drivers including innovation and expanding reach."
Dawn Allen, Chief Financial Officer
Strategic Positioning
1. Growth Through Innovation and Market Penetration
Haleon is prioritizing innovation-led premiumization, particularly in Oral Health and Pain Relief, with products like Sensodyne Clinical White and Otrivin Nasal Mist expanding into new markets. The company is also focused on closing the treatment gap by increasing penetration in under-served segments, such as lower-income consumers in India and Brazil, through affordable pack sizes and tailored offerings.
2. Supply Chain Productivity as a Margin Lever
The productivity program targets £800 million in gross supply chain savings over five years through SKU and formulation reduction, manufacturing efficiency improvements, and logistics optimization. Early results include a 16% SKU reduction and 5% formulation reduction since 2024, with manufacturing site transfers boosting volume capacity and reducing costs.
3. Balanced Investment in Brand Building and R&D
Despite margin expansion, Haleon increased A&P spend by 6.8% and R&D by 9.1%, emphasizing support for new product launches and evidence generation. This disciplined reinvestment aims to sustain market share gains and fuel medium-term growth.
4. Geographic Diversification Mitigates Regional Headwinds
Strong growth in EMEA, LatAm, and APAC offsets North American softness. The company’s broad global footprint and tailored regional strategies enable it to capitalize on growth markets while managing challenges in the U.S. consumer environment and retailer inventory management.
5. Capital Allocation Supporting Shareholder Returns and Strategic Flexibility
Haleon’s cash flow generation supports a £500 million share buyback program, dividend increases, and strategic acquisitions such as the full ownership of its China OTC joint venture. The company targets a net debt to adjusted EBITDA ratio around 2.5x to balance investment, M&A optionality, and credit strength.
Key Considerations
Haleon’s half-year results reflect a complex interplay of geographic growth disparities, operational improvements, and strategic investments. Key considerations for investors include:
- North America Recovery Timeline: The U.S. market remains subdued with inventory destocking and trade-down dynamics; management expects continued pressure through 2025 with a return to growth anticipated in 2026.
- Innovation Impact: New product launches and clinical claims, especially in Oral Health and Pain Relief, are critical to driving volume growth and premiumization, particularly in emerging markets.
- Productivity Program Execution: Early margin gains validate the supply chain simplification strategy, but sustained execution is essential to meet long-term savings and margin expansion targets.
- Advertising Spend Efficiency: Improved return on advertising investment supports sustained brand strength, but incremental spend must continue to deliver growth amid competitive pressures.
- Capital Allocation Discipline: Share buybacks, dividend growth, and strategic M&A balance shareholder returns with investment for growth, maintaining financial flexibility.
Risks
Risks include continued consumer weakness and retailer inventory management in North America, competitive pressures particularly in VMS and Respiratory Health categories, and execution risk in productivity initiatives. Regulatory and geopolitical uncertainties, especially in emerging markets, also pose potential challenges to growth and margin sustainability.
Forward Outlook
For the second half of 2025, Haleon expects:
- Organic revenue growth around 3.5%, with an improving trend in EMEA, LatAm, and APAC, while North America remains subdued.
- High single-digit organic operating profit growth driven by positive operating leverage from productivity and disciplined cost management.
Management highlighted ongoing investments in innovation, brand building, and supply chain productivity as key drivers supporting this outlook despite macroeconomic uncertainties.
Takeaways
Haleon’s H1 2025 results demonstrate the company’s ability to drive margin expansion and cash flow growth through productivity and brand investment, even as North American growth remains challenged. The strategic focus on innovation, geographic diversification, and operational efficiency underpins confidence in medium-term growth targets.
- Margin Expansion Enables Growth Investment: The 160 basis points gross margin gain from supply chain simplification provides financial flexibility to increase advertising and R&D spend without sacrificing profitability.
- Geographic Mix Drives Resilience: Strong volume and price growth in EMEA, LatAm, and APAC offset North American softness, highlighting the importance of a diversified footprint.
- Monitoring U.S. Inventory and Consumer Trends: Investors should watch for signs of stabilization in retailer inventories and consumer confidence in North America, which will be critical for volume recovery and share gains.
Conclusion
Haleon’s half-year performance reflects a well-executed balance of growth, productivity, and investment amid a challenging global consumer health landscape. The company’s upgraded profit guidance and strong cash flow position it well to navigate near-term headwinds while pursuing its medium-term strategic ambitions.
Industry Read-Through
Haleon’s results underscore broader consumer health industry dynamics, including the critical role of supply chain optimization in margin expansion and the increasing importance of innovation-led premiumization. The persistent challenges in the U.S. retail environment, with inventory destocking and channel shifts toward value and e-commerce, are likely to affect other consumer health players. Additionally, the emphasis on expanding access to lower-income consumers in emerging markets reflects a growing strategic focus across the sector to drive volume growth amid mature market saturation.